DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Hawkins G, McMahon AD, Twaddle S, et al. Stepping down
inhaled corticosteroids in asthma: Randomised controlled trial.
BMJ, 2003, 326:1115.
Hawkins GA, Weiss ST, Bleecker ER. Clinical consequences
of ADRbeta2 polymorphisms. Pharmacogenomics, 2008,
9:349–358.
Henke MO, Ratjen F. Mucolytics in cystic fibrosis. Paediatr
Respir Rev, 2007, 8:24–29.
Hobbs AJ, Higgs A, Moncada S. Inhibition of nitric oxide synthase
as a potential therapeutic target. Ann Rev Pharmacol
Toxicol, 1999, 39:191–220.
Holz GG, Kang G, Harbeck M, et al. Cell physiology of cAMP
sensor Epac. J Physiol, 2006, 577:5–15.
Houslay MD, Schafer P, Zhang KY. Keynote review:
Phosphodiesterase-4 as a therapeutic target. Drug Discov
Today, 2005, 10:1503–1519.
Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary
arterial hypertension. N Engl J Med, 2004, 351:1425–1436.
Ichiyama T, Hasegawa S, Matsubara T, et al. Theophylline
inhibits NF-B activation and IB degradation in human pulmonary
epithelial cells. Naunyn Schmiedebergs Arch
Pharmacol, 2001, 364:558–561.
Ito K, Lim S, Caramori G, et al. A molecular mechanism of
action of theophylline: Induction of histone deacetylase activity
to decrease inflammatory gene expression. Proc Natl Acad
Sci USA, 2002, 99:8921–8926.
Ito K, Yamamura S, Essilfie-Quaye S, et al. Histone deacetylase
2-mediated deacetylation of the glucocorticoid receptor
enables NF-B suppression. J Exp Med, 2006, 203:
7–13.
Jaeschke R, O’Byrne PM, Mejza F, et al. The safety of longacting
beta-agonists among patients with asthma using inhaled
corticosteroids: Systematic review and metaanalysis. Am J
Respir Crit Care Med, 2008, 178:1009–1016.
Jones PW, Greenstone M. Carbonic anhydrase inhibitors for hypercapnic
ventilatory failure in chronic obstructive pulmonary disease.
Cochrane Database Syst Rev, 2001, CD002881.
Karin M, Yamamoto Y, Wang QM. The IKK NF-kappa B system:
A treasure trove for drug development. Nat Rev Drug
Discov, 2004, 3:17–26.
Kidney J, Dominguez M, Taylor PM, et al. Immunomodulation
by theophylline in asthma: Demonstration by withdrawal of
therapy. Am J Resp Crit Care Med, 1995, 151:1907–1914.
Kips JC, Pauwels RA. Long-acting inhaled 2-agonist therapy in
asthma. Am J Respir Crit Care Med, 2001, 164:923–932.
Kirkham P, Rahman I. Oxidative stress in asthma and COPD:
antioxidants as a therapeutic strategy. Pharmacol Ther, 2006,
111:476–494.
Kishore N, Sommers C, Mathialagan S, et al. A selective IKK-2
inhibitor blocks NF-B-dependent gene expression in IL-1
stimulated synovial fibroblasts. J Biol Chem, 2003, 277:
13840–13847.
Larche M, Akdis CA, Valenta R. Immunological mechanisms of
allergen-specific immunotherapy. Nat Rev Immunol, 2006,
6:761–771.
Leckie MJ, ten Brincke A, Khan J, et al. Effects of an interleukin-
5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness
and the late asthmatic response. Lancet, 2000,
356:2144–2148.
Levy ML, Stevenson C, Maslen T. Comparison of short courses
of oral prednisolone and fluticasone propionate in the treatment
of adults with acute exacerbations of asthma in primary care.
Thorax, 1996, 51:1087–1092.
Lim S, Jatakanon A, Gordon D, et al. Comparison of high dose
inhaled steroids, low dose inhaled steroids plus low dose theophylline,
and low dose inhaled steroids alone in chronic
asthma in general practice. Thorax, 2000, 55:837–841.
Lim S, Tomita K, Carramori G, et al. Low-dose theophylline
reduces eosinophilic inflammation but not exhaled nitric oxide
in mild asthma. Am J Resp Crit Care Med, 2001, 164:273–276.
Linden A, Hansson L, Andersson A, et al. Bronchodilation by an
inhaled VPAC(2) receptor agonist in patients with stable
asthma. Thorax, 2003, 58:217–221.
Lotvall J, Palmqvist M, Arvidsson P, et al. The therapeutic ratio
of R-albuterol is comparable with that of RS-albuterol in asthmatic
patients. J Allergy Clin Immunol, 2001, 108:726–731.
Madaan A. Arformoterol tartrate in the treatment of bronchoconstriction
in patients with chronic obstructive pulmonary disease.
Drugs Today (Barc), 2009, 45:3–9.
Mak JCW, Nishikawa M, Shirasaki H, et al. Protective effects of
a glucocorticoid on down-regulation of pulmonary 2-
adrenergic
receptors in vivo. J Clin Invest, 1995, 96:99–106.
Manjra AI, Price J, Lenney W, et al. Efficacy of nebulized fluticasone
propionate compared with oral prednisolone in children
with an acute exacerbation of asthma. Resp Med, 2000,
94:1206–1214.
Manning P, Gibson PG, Lasserson TJ. Ciclesonide versus other
inhaled steroids for chronic asthma in children and adults.
Cochrane Database Syst Rev, 2008, CD007031.
Marwick JA, Caramori G, Stevenson CC, et al. Inhibition of
PI3K restores glucocorticoid function in smoking-induced
airway inflammation in mice. Am J Respir Crit Care Med,
2009, 179:542–548.
McGraw DW, Almoosa KF, Paul RJ, et al. Antithetic regulation
by -adrenergic receptors of Gq receptor signaling via phospholipase
C underlies the airway -agonist paradox. J Clin
Invest, 2003, 112:619–626.
McGraw DW, Liggett SB. Heterogeneity in beta-adrenergic
receptor kinase expression in the lung accounts for cell-specific
desensitization of the beta2- adrenergic receptor. J Biol
Chem, 1997, 272:7338–7344.
Mcivor RA, Pizzichini E, Turner MO, et al. Potential masking
effects of salmeterol on airway inflammation in asthma. Am J
Respir Crit Care Med, 1998, 158:924–930.
McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA
2009 expert consensus document on pulmonary hypertension.
J Am Coll Cardiol, 2009, 53:1573–1619.
McLeod RL, Correll CC, Jia Y, Anthes JC. TRPV1 antagonists
as potential antitussive agents. Lung, 2008 (186 suppl 1):
S59–S65.
Minoguchi K, Kohno Y, Minoguchi H, et al. Reduction of
eosinophilic inflammation in the airways of patients with
asthma using montelukast. Chest, 2002, 121:732–738.
Mohammed S, Goodacre S. Intravenous and nebulised magnesium
sulphate for acute asthma: Systematic review and metaanalysis.
Emerg Med J, 2007, 24:823–830.
Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular
basis of pulmonary arterial hypertension. J Am Coll Cardiol,
2009, 54:S20–S31.
Nathan RA. Pharmacotherapy for allergic rhinitis: A critical review
of leukotriene receptor antagonists compared with other treatments.
Ann Allergy Asthma Immunol, 2003, 90:182–190.
1063
CHAPTER 36
PULMONARY PHARMACOLOGY